NCT06908928View on ClinicalTrials.gov

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

PHASE1RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

bulumtatug fuvedotin

given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 1

DRUG

bulumtatug fuvedotin

given via intravenous infusion on day 1 and day 8 of every 21-day cycle at dose level 2

Trial Locations (5)

10021

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

60637

RECRUITING

UChicago Medicine Comprehensive Cancer Center, Chicago

91010

NOT_YET_RECRUITING

City of Hope, Duarte

92093

RECRUITING

UCSD Moores Cancer Center, La Jolla

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY